CureVac NV
CVAC5.425USD
+0.015+0.28%
交易中 （美东）报价延迟15分钟
1.22B总市值
6.76市盈率 TTM
关于 CureVac NV 公司
CureVac NV（前身为 CureVac AG）是一家总部位于德国的临床阶段生物制药公司。该公司开发基于信使核糖核酸 (mRNA) 的转化药物。该公司的 mRNA 旨在通过模仿人类生物学合成所需蛋白质来预防感染和治疗疾病。其技术平台优化了编码功能性蛋白质的 mRNA 构建体，这些蛋白质要么诱导所需的免疫反应，要么使用细胞固有的翻译机制替换有缺陷或缺失的蛋白质。该公司的产品组合包括预防性疫苗、肿瘤学和分子治疗等多种疾病适应症的临床和临床前候选药物。在预防性疫苗方面，该公司正在与葛兰素史克 (GSK) 合作，推进其针对严重急性呼吸道综合征冠状病毒 2 (SARS-CoV-2) 和一系列传染病（包括季节性流感）的第二代 mRNA 骨架。
公司简介
公司代码CVAC
公司名称CureVac NV
上市日期Aug 14, 2020
CEODr. Alexander Zehnder, M.D.
员工数量825
证券类型Ordinary Share
年结日Aug 14
公司地址Friedrich-Miescher-Str. 15
城市TUEBINGEN
上市交易所NASDAQ Global Market Consolidated
国家Germany
邮编72076
电话49707198830
网址https://www.curevac.com/
公司代码CVAC
上市日期Aug 14, 2020
CEODr. Alexander Zehnder, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Alexander Zehnder, M.D.
Dr. Alexander Zehnder, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Myriam Mendila, M.D.
Dr. Myriam Mendila, M.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
收入明细
单位: EUR更新时间: 7月6日 周日
单位: EUR更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
暂无数据
地区EUR
名称
营收
占比
Switzerland
586.00K
65.62%
Belgium (Country)
306.00K
34.27%
业务
地区
暂无数据
股东统计
更新时间: 7月23日 周三
更新时间: 7月23日 周三
持股股东
股东类型
持股股东
持股股东
占比
DH Capital GmbH & Co. KG
31.17%
KfW
13.27%
Glaxo Group, Ltd.
7.37%
DH-LT-Investments GmbH
3.89%
Zweite DH Verwaltungs GmbH
1.51%
Other
42.80%
持股股东
持股股东
占比
DH Capital GmbH & Co. KG
31.17%
KfW
13.27%
Glaxo Group, Ltd.
7.37%
DH-LT-Investments GmbH
3.89%
Zweite DH Verwaltungs GmbH
1.51%
Other
42.80%
股东类型
持股股东
占比
Corporation
36.61%
Government Agency
13.27%
Holding Company
7.37%
Investment Advisor
1.31%
Hedge Fund
0.93%
Investment Advisor/Hedge Fund
0.89%
Foundation
0.70%
Bank and Trust
0.41%
Research Firm
0.30%
Other
38.23%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
248
139.54M
61.97%
-14.77M
2025Q1
256
140.77M
62.52%
-15.67M
2024Q4
257
142.22M
63.40%
-15.15M
2024Q3
264
144.04M
64.21%
-15.50M
2024Q2
284
147.06M
65.56%
-13.88M
2024Q1
303
150.44M
67.06%
-10.89M
2023Q4
317
154.94M
69.64%
-16.33M
2023Q3
339
166.99M
75.03%
-5.02M
2023Q2
359
168.77M
75.83%
-4.22M
2023Q1
383
169.76M
76.27%
+21.54M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
DH Capital GmbH & Co. KG
70.18M
31.17%
--
--
Jun 12, 2025
KfW
29.87M
13.27%
--
--
Mar 15, 2025
Glaxo Group, Ltd.
16.59M
7.37%
--
--
Mar 15, 2025
DH-LT-Investments GmbH
8.75M
3.89%
--
--
Jun 12, 2025
Zweite DH Verwaltungs GmbH
3.40M
1.51%
--
--
Jun 12, 2025
Millennium Management LLC
1.82M
0.81%
+169.95K
+10.32%
Mar 31, 2025
Bill & Melinda Gates Foundation
1.57M
0.7%
-28.77K
-1.80%
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
598.13K
0.27%
-7.56K
-1.25%
Mar 31, 2025
UBS Switzerland AG
497.53K
0.22%
+424.90K
+585.03%
Mar 31, 2025
BlackRock Advisors (UK) Limited
347.00K
0.15%
+3.49K
+1.02%
Jun 30, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
Global X Genomics & Biotechnology ETF
0.65%
WisdomTree BioRevolution Fund
0.56%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
iShares Biotechnology ETF
0.05%
iShares MSCI Europe Small-Cap ETF
0.04%
iShares MSCI EAFE Small-Cap ETF
0.02%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.87%
Global X Genomics & Biotechnology ETF
占比0.65%
WisdomTree BioRevolution Fund
占比0.56%
ProShares Ultra Nasdaq Biotechnology
占比0.14%
Invesco Nasdaq Biotechnology ETF
占比0.14%
iShares Biotechnology ETF
占比0.05%
iShares MSCI Europe Small-Cap ETF
占比0.04%
iShares MSCI EAFE Small-Cap ETF
占比0.02%
Xtrackers MSCI Eurozone Hedged Eqty ETF
占比0.01%
Fidelity Nasdaq Composite Index ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
